Products for Research Use Only
RegisterLogin

Setrobuvir

CAT: 0804-HY-13247Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13247Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition[1][2].
CAS Number
1071517-39-9
Product Name Alternative
ANA598
UNSPSC
12352005
Target
DNA/RNA Synthesis; HCV; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/setrobuvir.html
Solubility
10 mM in DMSO
Smiles
CS(=O)(NC1=CC=C(C2=C1)N=C(C3=C(O)[C@]4([H])[C@@](C5)([H])CC[C@@]5([H])[C@]4([H])N(CC6=CC=C(F)C=C6)C3=O)NS2(=O)=O)=O
Molecular Formula
C25H25FN4O6S2
Molecular Weight
560.62
References & Citations
[1]Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56 (2) :830‐837.|[2]Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silicoperspective [published online ahead of print, 2020 May 6]. J Biomol Struct Dyn. 2020;1‐9.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
T28762-01Setrobuvir
MBS130534-01Setrobuvir,
MBS387616-01Setrobuvir (ANA-598)
A13105-500Setrobuvir (ANA-598) 500mg
A13105-10Setrobuvir (ANA-598) 10mg
A13105-50Setrobuvir (ANA-598) 50mg
A13105-25Setrobuvir (ANA-598) 25mg
A13105-1Setrobuvir (ANA-598) 1mg
A13105-100Setrobuvir (ANA-598) 100mg
A13105-5Setrobuvir (ANA-598) 5mg

Popular Products